By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on SMCI, with the immediate capital raise seen as dilutive and the $39B backlog's margin upside uncertain. The key risk is the timing of backlog conversion and the potential for dilution to compress ROE. The key opportunity lies in SMCI's ability to prove margin expansion within 18 months, making the dilution palatable.
Risk: The timing of backlog conversion and potential dilution compressing ROE
Opportunity: Proving margin expansion within 18 months
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Investors are bailing on Super Micro Computer (SMCI) shares on June 10 after the artificial intelligence (AI) infrastructure company announced a $5 billion underwritten public offering. In its press release, management disclosed a separate $2 billion at-the-market (ATM) equity program as well to “fund the purchase of components” necessary to fulfill customer orders.
Following today’s decline, Super Micro stock is down about 35% versus its recent high.
SMCI is about to flood the market with new shares worth some $1.25 billion; the remaining is in depository shares representing mandatory convertible preferred stock that doesn't come online until mid-2029.
For investors, what this simply means is a multi-year dilution overhang — one that incrementally erodes per-share economics and weighs on the broader thesis surrounding Super Micro Computer Inc.
Additionally, now that SMCI stock has slipped below its 20-day moving average (MA), it is well within reason to assume that the bearish sentiment might just sustain in the near term.
Investors should also note that Super Micro's relative strength index (14-day) is hovering around 41 currently, indicating more room to the downside before the stock hits oversold territory.
In its press release, management cited about $39 billion in recent AI server orders from more than 20 customers as justification for the capital raise.
But that backlog hasn’t yet translated into pricing power or margin strength investors can rely on; gross margin in the latest reported quarter stood at just 9.9%, which is thin for a company tapping equity markets at this scale.
For investors already skittish about Super Micro governance history, a combination of heavy dilution and razor-thin margins makes today’s selloff a no-go for buy-the-dip enthusiasts.
Note that SMCI has a history of gaining just 2.9% in July, followed by a more than 7% decline in August — a seasonal pattern that makes it rather unattractive to own in the near term.
Four leading AI models discuss this article
"The immediate dilution overhang from the $7B raise creates a persistent drag on per-share value unless backlog conversion and margin improvement materialize."
SMCI faces an immediate capital raise that could dilute shareholders for years, but the money is also earmarked to fulfill a $39B backlog, which, if converted efficiently, could unlock scale-driven margin upside. The article highlights 9.9% gross margin today—pointed to as a weakness—but at scale, mix optimization and commodity pricing could move margins higher; the real risk is timing: the new shares start trading on dilution now, with the depository preferred not online until 2029. Near-term price action likely remains weak, but if backlog conversion accelerates, the bear case could fade.
Counterpoint: the capital raise funds operational scale rather than just diluting equity; if SMCI can convert backlog to revenue quickly and stabilize margins, the stock could rebound faster than skeptics expect. The upside hinges on execution, not just the headline dilution.
"SMCI's razor-thin gross margins indicate that the company lacks the pricing power necessary to justify its current valuation, regardless of the size of its AI backlog."
The market is fixating on the $7 billion dilution, but the real story is the 9.9% gross margin. In a high-growth AI infrastructure cycle, such thin margins on $39 billion in backlog suggest SMCI is functioning more as a low-margin integrator than a high-value hardware innovator. While the equity raise provides liquidity to clear supply chain bottlenecks, it essentially forces shareholders to subsidize the company’s inability to capture pricing power. With the stock breaking its 20-day moving average, the technical setup is deteriorating. Unless management can prove these massive orders carry higher margin profiles, this capital raise is a desperate move to maintain scale at the expense of shareholder value.
If the $39 billion backlog is successfully converted to revenue, the massive scale could lead to economies of scale that eventually expand margins and justify the dilution as a necessary bridge to market dominance.
"The dilution is real but secondary to whether SMCI can prove gross margin expansion justifies the capital raise—a question the article doesn't adequately stress-test."
The article frames this as unambiguous dilution doom, but conflates two distinct capital structures. The $5B underwritten offering dilutes immediately (~$1.25B in common equity); the $2B mandatory convertible doesn't convert until mid-2029—that's a 5-year runway to grow into it or refinance it away. At $39B in backlog, SMCI needs capital NOW to fulfill orders and capture market share in a capacity-constrained AI infrastructure market. The real risk isn't dilution per se—it's whether 9.9% gross margins expand as volumes scale. The article's seasonal pattern argument (2.9% July gain, 7% August decline) is cherry-picked noise masquerading as signal. What matters: can SMCI convert backlog into 12%+ gross margins within 18 months?
If SMCI's margins stay stuck at 9.9% despite $39B in orders, the capital raise funds a low-return business, and the convertible becomes a sword of Damocles that forces dilution or refinancing in a worse market. Backlog ≠ profitability.
"Heavy dilution at thin 9.9% gross margins creates a multi-year overhang that outweighs the unproven AI backlog."
SMCI's $5B underwritten offering plus $2B ATM program will dilute shares materially while the $39B AI backlog has yet to produce sustainable margins—gross margin was just 9.9% last quarter. The move below the 20-day MA and RSI near 41 point to continued near-term pressure. Governance history adds another layer of skepticism around execution. Seasonal weakness in July-August compounds the risk that investors will avoid the name until clearer evidence of operating leverage appears. The capital raise essentially front-loads dilution before revenue converts to earnings.
The $39B orders could drive a multi-year revenue surge that renders the dilution percentage negligible if volume growth triggers meaningful margin expansion and pricing power.
"The dilution is only palatable if SMCI can deliver 12%+ gross margins within 18 months; otherwise, backlog size won’t justify the equity dilution."
Gemini overemphasizes pricing power risk while ignoring the execution hinge: even if backlog converts, the margin path needs visible scale levers to move from 9.9% to teens; without that, dilution compresses ROE and keeps the stock hostage to backlog timing. The real crucible is proof-of-delivered margin leverage, not backlog size. If management guides 12%+ gross margins within 18 months, the dilution becomes palatable; otherwise, it's a perpetual drag.
"The validity of the $39B backlog is secondary to the company's governance and accounting transparency, which remain the primary risks to shareholder value."
Claude, you dismiss the governance risk, but that is the primary filter for the backlog's validity. If SMCI's internal controls are as opaque as recent auditor concerns suggest, that $39B backlog is not a guarantee of future revenue—it is a potential liability. We are debating margin expansion while ignoring that the capital raise might be a liquidity bridge for accounting-related cash burn rather than pure operational scaling. Execution is impossible without transparent, reliable reporting.
"Governance risk is real, but it's an execution/reporting tax on the backlog, not proof the backlog is fictitious."
Gemini flags governance opacity as a backlog validity filter—valid concern—but conflates two risks. Opaque controls threaten *reported* margins and cash burn, not necessarily backlog authenticity. If $39B orders are real customer commitments (verifiable via customer disclosures, SEC filings), governance weakness affects execution risk and margin credibility, not order existence. The capital raise could still fund real revenue even if internal controls are weak. That's worse for shareholders, not better—you're funding a company you can't trust to report accurately.
"Governance weakness turns the capital raise into funding for unverifiable margin outcomes rather than scalable growth."
Gemini rightly links governance opacity to execution risk, but the unaddressed flaw is that unreliable internal controls will prevent investors from verifying whether the $39B backlog actually drives margin expansion after dilution hits. Without credible reporting on cash conversion and gross margins, the $5B raise funds a black box where 9.9% margins could persist indefinitely, making Claude's distinction between backlog authenticity and margin credibility largely academic for shareholders.
The panel consensus is bearish on SMCI, with the immediate capital raise seen as dilutive and the $39B backlog's margin upside uncertain. The key risk is the timing of backlog conversion and the potential for dilution to compress ROE. The key opportunity lies in SMCI's ability to prove margin expansion within 18 months, making the dilution palatable.
Proving margin expansion within 18 months
The timing of backlog conversion and potential dilution compressing ROE